Individuals can determine the side of the nose that receives an odorant during unilateral presentation (lateralize) if endings of the trigeminal nerve are stimulated. By using psychophysical methods, olfactory detection and trigeminal lateralization thresholds for 1-butanol were obtained from 142 individuals ranging in age from 20 to 89 year. Sensitivity in both chemosensory pathways declined with advancing age, especially in people older than 60 years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3758/bf03194788 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Autonomic features of craniofacial neuralgias: a systematic review with meta-analysis.
J Oral Facial Pain Headache
September 2024
Light Dental Studios, Puyallup, WA 98371, USA.
The aim of the study is to describe the severity, temporal characteristics, and types of autonomic features as they relate to the characteristics of pain of the neuralgias. Also, to describe, based on literature, how these autonomic features can affect the treatment outcomes of patients with craniofacial neuralgias. We carried out a literature search using five databases, PubMed, Embase, OVID, Scopus and Web of Science.
View Article and Find Full Text PDFRevolutionizing Parkinson's treatment: Harnessing the potential of intranasal nanoemulsions for targeted therapy.
Drug Deliv Transl Res
January 2025
Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra, 136119, Haryana, India.
Parkinson's disease (PD) is the most prominent and highly prevalent chronic neuro-degenerative disease generally recognized by classical motor symptoms which are linked with genetic mutation, Lewy bodies, and subsequently selective loss of nigrostriatal dopaminergic neurons. The blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier protect the central nervous system against toxins and are the most significant barriers to effective brain drug delivery in managing Parkinsonism. In recent years, intranasal delivery has attracted remarkable attention for brain targeting as the drug can be administered to the brain directly from the nose employing the trigeminal and olfactory pathways.
View Article and Find Full Text PDFAdvancements in nose-to-brain drug targeting for Alzheimer's disease: a review of nanocarriers and clinical insights.
Inflammopharmacology
January 2025
Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India.
Alzheimer's disease (AD) is a type of neurodegenerative disease that describes cognitive decline and memory loss resulting in disability in movement, memory, speech etc. Which first affects the hippocampal and entorhinal cortex regions of brain. Pathogenesis of AD depends on Amyloid-β, hyper-phosphorylation of tau protein, mitochondrial dysfunction, cholinergic hypothesis and oxidative stress.
View Article and Find Full Text PDFNanosystems at Nexus: Navigating Nose-to-Brain Delivery for Glioblastoma Treatment.
Mol Pharm
January 2025
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad, Palaj, Gandhinagar 382355, Gujarat, India.
Glioblastoma multiforme (GBM) is considered to be one of the most devastating brain tumors with a shorter life expectancy. Several factors contribute to the dismal prognosis of GBM patients including the complicated nature of GBM, the ability of tumor cells to resist treatment, and the difficulty of delivering drugs to the brain because of barriers like the blood-brain barrier (BBB) and blood-tumor barrier (BTB). The unique challenges posed by the BBB in delivering therapeutic agents to the brain have led to the development of innovative nanotechnology-based approaches.
View Article and Find Full Text PDFTRPA1 contributes to respiratory depression from tobacco aerosol.
Respir Physiol Neurobiol
January 2025
Department of Physiology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. Electronic address:
Transient receptor potential ankyrin-1 (TRPA1) is expressed in the trigeminal nerves in the nasal cavity. It detects irritant chemicals such as formalin and acrolein, induces respiratory depression to protect against further inhalation, and elicits avoidance behavior. Although tobacco smoke contains formalin, acrolein, and other irritant chemicals, the possible contribution of TRPA1 to protection against tobacco smoke has yet to be fully understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!